LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

Search

ADMA Biologics Inc

Open

SectorGezondheidszorg

20.72 -3.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.5

Max

21.77

Belangrijke statistieken

By Trading Economics

Inkomsten

-85M

27M

Verkoop

-2.7M

115M

K/W

Sectorgemiddelde

24.845

51.748

EPS

0.136

Winstmarge

23.435

Werknemers

685

EBITDA

-4.7M

35M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+41.99% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.2B

5B

Vorige openingsprijs

24.08

Vorige sluitingsprijs

20.72

Nieuwssentiment

By Acuity

20%

80%

37 / 380 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

ADMA Biologics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 apr 2025, 14:13 UTC

Belangrijke Marktbewegers

ADMA Biologics Shares Hit 52-Week High After FDA Approval

Peer Vergelijking

Prijswijziging

ADMA Biologics Inc Prognose

Koersdoel

By TipRanks

41.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30.67 USD  41.99%

Hoogste 35 USD

Laagste 25 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor ADMA Biologics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 23.5406Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

37 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.